Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

subject to a final decision by the European Commission, usually rendered approximately 60 to 90 days after the CHMP's recommendation. In preparation for potential marketing authorization and commercialization, NeurogesX has continued active discussions with potential European marketing partners and anticipates completing a transaction in the first half of 2009.

Qutenza is also undergoing U.S. regulatory review, and the United States Food and Drug Administration (FDA) has scheduled a Prescription Drug User Fee Act (PDUFA) date of August 16, 2009 to review the new drug application (NDA) for the management of pain associated with postherpetic neuralgia (PHN).

Anthony DiTonno, President and CEO, commented, "We are confident that Qutenza is closer than ever to commercialization as we await the European Commission's decision on our MAA, expected within the coming weeks. We are in late stage discussions with potential European commercial partners for Qutenza, supported by the proposed broad E.U. label for peripheral neuropathic pain conditions in non-diabetic adults, either alone or in combination with other medicinal products for pain. We also continue to plan for the potential U.S. commercialization of Qutenza. Our top priority remains to secure U.S. and European regulatory approvals and become a commercial-stage company. We look forward to several upcoming milestones in 2009."

First Quarter 2009 Financial Results

Total operating expenses for the first quarter of 2009 were approximately $4.5 million, down 46% from approximately $8.3 million in the same period of 2008. The decrease primarily resulted from a $3.5 million decrease in research and development costs. Year-over-year operating expenses were lower as the Company deferred development programs in order to focus resources on regulatory processes and to continue preparations for potential commercialization of Qutenza in both Europe and the
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... July 03, 2015 , ... The Alexander ... and professional service industries alike-- typically known for its consummate professionalism-- embarks each ... good cause and break from their day jobs. , "Our motto has always ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... The global ... of 7.52% from 2015 to 2020. The bioscience market is expected to grow at ... increased use of failure analysis equipment in the research labs and academic institutions for ...
(Date:7/3/2015)... Forskare kan ansöka ... http://www.openinnovationinscience.at till det återkommande utbildningsprogrammet "Lab ... i Wien .  ... forskare och vetenskapsmän som genomfördes av Ludwig ... utmaningar bristen på incitament för att undersöka ...
(Date:7/3/2015)... 2015 Forskere kan ... in Science", som finner sted i ... nett, på  http://www.openinnovationinscience.at , og søknadsperioden varer ... De to største utfordringene innen helsevitenskapen er ... forskningsspørsmål og kompleksiteten av nåværende forskningsresultater, i ...
Breaking Biology Technology:The Alexander Group Declares Their Independence with a Bit of Levity 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3
... 10 , - Nerviano ... the CDC7,Inhibitor , Nerviano Medical ... to conduct for the first time clinical trials of ... that is responsible for,the uncontrolled proliferation of cancer cells. ...
... ADVENTRX Pharmaceuticals, Inc.,(NYSE Alternext US: ANX) announced today ... numerous companies representing a range of,strategic transactions. ... In December 2008, the Company announced that ... the sale or disposition of one or more ...
... Israel, Feb. 10 Modigene Inc. (OTC Bulletin ... set the close of business on April 1, 2009 as ... Company,s 2009 Annual Meeting of Shareholders. Modigene currently anticipates ... 21, 2009 in Miami, Florida at a location to be ...
Cached Biology Technology:FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers 2ADVENTRX Provides Update on Strategic Transaction Process 2ADVENTRX Provides Update on Strategic Transaction Process 3ADVENTRX Provides Update on Strategic Transaction Process 4Modigene Sets Record Date for Annual Meeting of Shareholders 2
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... Philadelphia, PA, March 13, 2013 Many Canadians are ... reduce sodium intake through a variety of measures, including ... to a national survey. The top barriers to limiting ... and processed foods and lower sodium restaurant menu options. ...
... and other woody debris that are inevitable byproducts of ... of post-harvest landscapes, according to a new study led ... Researchers found that retaining moderate levels ... both directly and indirectly increase the growth rate of ...
... almost 50 percent less likely than their male counterparts ... (SABs) and start new companies mainly because of gender ... assistant professor of management at the Robert H. Smith ... leadership and business savvy, and are not capable of ...
Cached Biology News:Canadians support interventions to reduce dietary salt 2Logging debris gives newly planted Douglas-fir forests a leg-up 2Stereotyping prime obstacle to women in commercial science 2
...
Tissue-Stat ( Tissue Adherent for Mounting Formalin-Fixed and Frozen Tissue Sections.)...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
Biology Products: